Analyst
Nephron Research
Equibles does not estimate personal net worth.
Jack Meehan is recorded as Analyst at Nephron Research. Jack Meehan has spoken on 42 earnings calls and 1 other investor event across 17 companies, most recently for Qiagen N.V. on August 6, 2026. Those appearances were for Agilent Technologies, Inc. (A), Thermo Fisher Scientific Inc. (TMO), Quest Diagnostics Inc (DGX), Bio-Rad Laboratories, Inc. (BIO), Labcorp Holdings Inc. (LH) and 12 other companies. The companies whose calls Jack Meehan spoke on are classified in the Healthcare sector.
“For Thierry, so you've announced the strategic review and still have the CEO search going on. I was wondering, how should we view the status of the strategic review when a new CEO is named?”
“I was wondering, just because we've seen it seems like you're hiring to support that launch, can you give us a quick update on what the reimbursement situation is for that?”
“First question, I wanted to follow up on Tyco's second question, more around the cost actions, though. So you've built in $75 million for 2026 with a $200 million run rate.”
“I wanted to push a little bit more on the diagnostic lab organic growth. You know, the 3.6%, that's nothing to scoff at here, but, you know, it comes after, you know, a notably stronger print from your closest peer.”
“I wanted to dig a little bit more into the life science business, specifically start with Paul Industrial.”
Nephron Research
Analyst
Source not stated
Diagnostics & Research · Healthcare
Diagnostics & Research · Healthcare
Diagnostics & Research · Healthcare
Diagnostics & Research · Healthcare
DHR
Diagnostics & Research · Healthcare
BRKR
Medical Devices · Healthcare
QGEN
Diagnostics & Research · Healthcare
QDEL
Medical Devices · Healthcare
Diagnostics & Research · Healthcare
WAT
Diagnostics & Research · Healthcare
ILMN
Diagnostics & Research · Healthcare
AVTR
Medical Instruments & Supplies · Healthcare
